FDA Nicotine Pouch PMTA Pipeline: Every Pending Application (July 2026 Update)

TL;DR

As of July 2, 2026, the FDA has authorized only 26 nicotine pouch SKUs from two brands: ZYN (20 SKUs) and on! PLUS (6 SKUs). Major brands including VELO, Rogue, Lucy, and FRE have submitted premarket tobacco product applications (PMTAs) but have not yet received FDA marketing authorization, with most applications pending review for nearly six years since the September 2020 deadline.

Understanding the PMTA Pipeline

The FDA's premarket tobacco product application process requires manufacturers to demonstrate that their products are "appropriate for the protection of public health" before receiving marketing authorization. For nicotine pouches, this means submitting extensive data on product chemistry, toxicology, user behavior, and potential impact on youth initiation and adult cessation patterns.

The September 9, 2020 deadline established under the Tobacco Control Act created a massive application backlog at the FDA's Center for Tobacco Products. The agency received over 6.5 million applications for various tobacco products, with nicotine pouches representing a small but commercially significant subset.

Current FDA Authorization Status by Brand

ZYN: The First Major Authorization

Swedish Match's ZYN received FDA marketing authorization for all 20 submitted SKUs on January 16, 2025, marking the first major nicotine pouch brand to clear the PMTA process. The authorization covers 10 flavors (Coffee, Cinnamon, Citrus, Cool Mint, Peppermint, Smooth, Spearmint, Wintergreen, Chill, Coffee) in both 3mg and 6mg strengths, with 15 pouches per can.

The FDA's decision was based on Swedish Match's submission of behavioral data showing the product appealed primarily to adult tobacco users rather than youth non-users, along with toxicological evidence demonstrating reduced harm potential compared to combustible cigarettes.

on! PLUS: Selective Authorization

Helix Innovations, an Altria subsidiary, received authorization for six on! PLUS SKUs on December 19, 2025. Notably, the FDA authorized only the 6mg and 9mg variants in three flavors (Mint, Tobacco, Wintergreen), with 20 pouches per can. The on! PLUS Mint 3mg variant was not included in the authorization, suggesting the FDA evaluated each strength level independently for public health impact.

Brands Still Awaiting FDA Decisions

VELO (R.J. Reynolds Vapor / BAT)

VELO, manufactured by R.J. Reynolds Vapor Company (part of British American Tobacco), has submitted a PMTA but has not yet received FDA marketing authorization as of July 2026. The brand offers 20 pouches per can across multiple flavors and strengths. VELO remains on the market during the review period, but cannot make modified risk claims without separate authorization.

Rogue (Swisher International)

Swisher International's Rogue brand has submitted a PMTA but lacks FDA marketing authorization as of July 2026. With 20 pouches per can and a range of flavors, Rogue continues distribution while pending FDA review. The timeline for a decision remains uncertain.

Lucy (Lucy Goods Inc.)

Lucy Goods Inc. has submitted a PMTA for its Lucy brand, which features 15 pouches per can. The application remains under FDA review with no authorization granted as of July 2026. Lucy's slim-format pouches and flavor portfolio await regulatory clarity.

FRE (Turning Point Brands)

Turning Point Brands' FRE nicotine pouches (20 pouches per can) have a submitted PMTA that remains pending FDA review. No marketing authorization has been granted as of July 2026.

What Pending Status Means for Consumers

Products with pending PMTAs can legally remain on the market during FDA review under enforcement discretion policies. However, pending status provides no guarantee of eventual authorization. The FDA can issue marketing denial orders at any point during review if the application fails to demonstrate appropriate public health standards.

Consumers should understand that "PMTA submitted" is fundamentally different from "FDA authorized." Only products with explicit FDA marketing granted orders have undergone full regulatory review and met the agency's public health standard.

Industry Implications

The slow pace of PMTA decisions creates regulatory uncertainty for manufacturers, retailers, and investors. Brands operating with pending applications face potential market disruption if the FDA issues denial orders after years of review. Conversely, authorized brands like ZYN and on! PLUS gain significant competitive advantages through regulatory certainty and the ability to differentiate their FDA status in marketing.

The selective authorization of on! PLUS variants (6mg/9mg only, excluding 3mg) signals the FDA may evaluate individual SKUs based on strength-level risk profiles, potentially complicating future authorization strategies for multi-strength product lines.

What Happens Next

The FDA has provided no public timeline for resolving the remaining nicotine pouch PMTA backlog. Applications submitted in September 2020 are approaching their sixth year under review. Industry observers expect additional decisions in 2026-2027, but the agency's prioritization criteria remain opaque.

Manufacturers with pending applications can submit additional data or respond to FDA information requests during review. Some companies may pursue modified risk tobacco product (MRTP) applications for authorized products, seeking permission to make comparative harm reduction claims.

Consumers and industry stakeholders can monitor official updates through the FDA's tobacco products webpage, which publishes marketing orders and regulatory actions as they occur.

Verification and Transparency

This data reflects publicly available information from FDA announcements and manufacturer disclosures as of July 2, 2026. For brands not explicitly mentioned in FDA marketing orders, we report pending status based on the September 2020 PMTA deadline and continued market presence. Specific submission details (variant counts, flavor portfolios) may not be publicly disclosed for pending applications.

The nicotine pouch regulatory landscape continues evolving. Consumers should verify product authorization status directly through FDA.gov resources rather than relying solely on manufacturer claims or third-party summaries.